TABLE OF CONTENTS

CERTIFICATES

ACKNOWLEDGEMENT

LIST OF ABBREVIATIONS AND SYMBOLS

LIST OF FIGURES

LIST OF TABLES

PAGE NO.

CHAPTER 1 1

INTRODUCTION 1

CHAPTER 2 8

LITERATURE REVIEW 8

2.1. BRAIN CANCER AND TREATMENT 8
2.2. RESVERATROL 9
2.3. PHYSICO CHEMICAL PROPERTIES OF RSV 10
2.4. THERAPEUTIC POTENTIAL OF RSV 10
2.4.1. RSV against myocardial infarction and cardioprotection 10
2.4.2. RSV against platelet aggregation 11
2.4.3. RSV against stroke and brain damage 12
2.4.4. RSV against oxidative stress and inflammation 12
2.4.5. RSV against obesity and diabetes 13
2.4.6. RSV in vasodilation 14
2.4.7. RSV against cholesterol and triglycerides deposition 14
2.4.8. RSV against cancer prevention and glioma 14
2.5. PROBLEM WITH RSV FOR THERAPEUTIC APPLICATIONS 16
2.6. NANOFORMULATIONS OF RSV 16
2.7. TPGS 19
2.8. TPGS BASED FORMULATIONS IN CANCER DIAGNOSIS AND THERAPY 20
2.8.1. TPGS emulsified PLGA nanoparticles 20
2.8.2. Drug conjugated TPGS prodrug in cancer therapy 23
2.8.3. TPGS coated liposomes in cancer diagnosis and therapy 24
2.8.4. TPGS in micelles for cancer diagnosis and therapy 27
2.9. TPGS COPOLYMER BASED NANOMEDICINE IN CANCER DIAGNOSIS AND THERAPY 30
2.10. DSPE PEG 2000 AND PEGYLATED NANOPARTICLES 38

CHAPTER 3 44

OBJECTIVES AND PLAN OF WORK 44

3.1. OBJECTIVES 44
3.2. PLAN OF WORK 45

CHAPTER 4 46

MATERIALS AND METHODS 46

4.1. MATERIALS 46
4.2. HPLC ANALYTICAL METHOD 47
4.3. PREPARATION METHODS 48
4.3.1. Solid lipid nanoparticles 48
4.3.2. Blend nanoparticles 51
4.3.3. Core-shell polymer-lipid hybrid nanoparticles 54
4.3.4. Liposomes 57
4.4. PARTICLE SIZE, POLYDISPERSITY INDEX AND ZETA POTENTIAL 60
4.5. ENTRAPMENT EFFICIENCY 61
4.6. SHAPE OF NANOFORMULATIONS 61
4.7. *IN VITRO* DRUG RELEASE 61
4.8. DRUG EXCIPIENT INTERACTION ANALYSIS 62
4.9. DIFFERENTIAL SCANNING CALORIMETRIC (DSC) ANALYSIS 62
4.10. X-RAY DIFFRACTION ANALYSIS 63
4.11. CYTOTOXICITY AGAINST C6 GLIOMA CELLS 63
4.12. CELLULAR UPTAKE OF COUMARIN-6 LOADED NANOFORMULATIONS 64
4.13. EVALUATION OF HAEMOLYSIS 65
4.14. EVALUATION OF ERYTHROCYTE MEMBRANE INTEGRITY 66
4.15. PLATELET AGGREGATION 67
4.16. PHARMACOKINETIC STUDIES 68
4.17. TISSUE DISTRIBUTION STUDIES 70
4.18. STATISTICAL ANALYSIS 70

CHAPTER 5 72

RESULTS AND DISCUSSION 72

5.1. HPLC ANALYTICAL METHOD 72
5.2. SOLID LIPID NANOPARTICLES 74
5.2.1. Particle size, polydispersity index and zeta potential 74
5.2.2. Entrapment efficiency 76
5.2.3. Selection of best formulation 78
5.2.4. Shape of SLN formulations 78
5.2.5. In vitro drug release 79
5.2.6. Drug excipient compatibility studies 81

5.2.7. DSC analysis *84*
5.2.8. X-Ray diffraction analysis *85*
5.2.9. Cytotoxicity against C6 glioma cells *86*
5.2.10. Cellular uptake of Coumarin-6 loaded SLN *88*
5.2.11. Evaluation of haemolysis *90*
5.2.12. Evaluation of erythrocyte membrane integrity *92*
5.2.13. Platelet aggregation *95*
5.2.14. Pharmacokinetic studies *99*
5.2.15. Tissue distribution studies *103*
5.2.16. Comparative results of RSV-TPGS-SLN and RSV-PEG-SLN *107*
5.3. BLEND NANOPARTICLES 108
5.3.1. Particle size, polydispersity index and zeta potential *109*
5.3.2. Entrapment efficiency *112*
5.3.3. Selection of best formulation *114*
5.3.4. Shape of RSV-PLGA-BNPs *114*
5.3.5. In vitro drug release *115*
5.3.6. Drug interaction analysis *116*
5.3.7. DSC analysis *118*
5.3.8. X-Ray diffraction analysis *119*
5.3.9. Cytotoxicity against C6 glioma cells *119*
5.3.10. Cellular uptake *121*
5.3.11. Evaluation of haemolysis *122*
5.3.12. Evaluation of erythrocyte membrane integrity *124*
5.3.13. Platelet Aggregation *124*
5.3.14. Pharmacokinetic studies *127*
5.3.15. Tissue distribution studies *130*
5.3.16. Concluding results of RSV-PLGA-BNPs *133*
5.4. CORE-SHELL POLYMER-LIPID HYBRID NANOPARTICLES 134
5.4.1. Particle size, poly dispersity index and zeta potential *135*
5.4.2. Entrapment efficiency *137*
5.4.3. Selection of best formulation *138*
5.4.4. Shape of HNPs *139*
5.4.5. In vitro drug release *139*
5.4.6. Drug-excipient interaction analysis *141*
5.4.7. DSC analysis *144*
5.4.8. Analysis of crystalinity *145*
5.4.9. Cytotoxicity studies *146*
5.4.10. Cellular uptake of HNPs *148*
5.4.11. Evaluation of haemolysis *150*
5.4.12. Evaluation of erythrocyte membrane integrity *152*
5.4.13. Platelet Aggregation *154*

5.4.14. Pharmacokinetic studies *158*
5.4.15. Tissue distribution studies *162*
5.4.16. Comparative results of RSV-TPGS-HNPs and RSV-PEG-HNPs *166*
5.5. LIPOSOMES 167
5.5.1. Vesicular size, polydispersity index and zeta potential *168*
5.5.2. Encapsulation efficiency *171*
5.5.3. Selection of optimized formulations *172*
5.5.4. Shape of liposomes *173*
5.5.5. In vitro drug release *174*
5.5.6. Drug-excipient interaction analysis *177*
5.5.7. DSC analysis *180*
5.5.8. Crystalinity analysis *181*
5.5.9. In vitro cytotoxicity studies *182*
5.5.10. Cellular uptake of Coumarin-6 loaded liposomes *183*
5.5.11. Evaluation of haemolysis *185*
5.5.12. Erythrocyte membrane integrity *187*
5.5.13. Platelet aggregation *189*
5.5.14. Pharmacokinetic studies *193*
5.5.15. Tissue distribution studies *198*
5.5.16. Comparative results of RSV-TPGS-Lipo and RSV-PEG-Lipo *202*

CHAPTER 6 203

SUMMARY AND CONCLUSION 203

6.1. SUMMARY OF RESULTS 203
6.2. CONCLUSION 212

REFERENCES 213

LIST OF PUBLICATIONS 251

REPRINTS OF PUBLISHED PAPERS

PERSONAL PROFILE